Perspectives  ||| S:0 E:13 ||| NNP
of  ||| S:13 E:16 ||| IN
an  ||| S:16 E:19 ||| DT
innovative  ||| S:19 E:30 ||| JJ
ophthalmological  ||| S:30 E:47 ||| JJ
technology ||| S:47 E:57 ||| NN
:  ||| S:57 E:59 ||| :
optical  ||| S:59 E:67 ||| JJ
coherence  ||| S:67 E:77 ||| NN
tomography  ||| S:77 E:88 ||| NNS
( ||| S:88 E:89 ||| -LRB-
OCT ||| S:89 E:92 ||| NNP
) ||| S:92 E:93 ||| -RRB-
--what  ||| S:93 E:100 ||| NNP
should  ||| S:100 E:107 ||| MD
be  ||| S:107 E:110 ||| VB
of  ||| S:110 E:113 ||| IN
interest  ||| S:113 E:122 ||| NN
to  ||| S:122 E:125 ||| TO
the  ||| S:125 E:129 ||| DT
neurologist ||| S:129 E:140 ||| NN
?  ||| S:140 E:142 ||| .
Ocular  ||| S:142 E:149 ||| FW
coherence  ||| S:149 E:159 ||| FW
tomography  ||| S:159 E:170 ||| FW
has  ||| S:170 E:174 ||| VBZ
revolutionised  ||| S:174 E:189 ||| VBG
the  ||| S:189 E:193 ||| DT
prospects  ||| S:193 E:203 ||| NNS
of  ||| S:203 E:206 ||| IN
measuring  ||| S:206 E:216 ||| VBG
the  ||| S:216 E:220 ||| DT
loss  ||| S:220 E:225 ||| NN
of  ||| S:225 E:228 ||| IN
retinal  ||| S:228 E:236 ||| JJ
ganglion  ||| S:236 E:245 ||| NN
cells  ||| S:245 E:251 ||| NNS
secondary  ||| S:251 E:261 ||| JJ
to  ||| S:261 E:264 ||| TO
degenerative  ||| S:264 E:277 ||| VB
diseases  ||| S:277 E:286 ||| NNS
and  ||| S:286 E:290 ||| CC
monitoring  ||| S:290 E:301 ||| VBG
time-dependent  ||| S:301 E:316 ||| JJ
changes  ||| S:316 E:324 ||| NNS
of  ||| S:324 E:327 ||| IN
optic  ||| S:327 E:333 ||| JJ
disc  ||| S:333 E:338 ||| NN
morphology ||| S:338 E:348 ||| NN
,  ||| S:348 E:350 ||| ,
since  ||| S:350 E:356 ||| IN
the  ||| S:356 E:360 ||| DT
resolution  ||| S:360 E:371 ||| NN
has  ||| S:371 E:375 ||| VBZ
been  ||| S:375 E:380 ||| VBN
improved  ||| S:380 E:389 ||| VBN
considerably  ||| S:389 E:402 ||| RB
and  ||| S:402 E:406 ||| CC
the  ||| S:406 E:410 ||| DT
time  ||| S:410 E:415 ||| NN
required  ||| S:415 E:424 ||| VBN
has  ||| S:424 E:428 ||| VBZ
been  ||| S:428 E:433 ||| VBN
reduced ||| S:433 E:440 ||| VBN
.  ||| S:440 E:442 ||| .
Although  ||| S:442 E:451 ||| IN
the  ||| S:451 E:455 ||| DT
non-invasive  ||| S:455 E:468 ||| JJ
technique  ||| S:468 E:478 ||| NN
promises  ||| S:478 E:487 ||| VBZ
a  ||| S:487 E:489 ||| DT
high  ||| S:489 E:494 ||| JJ
inter-session  ||| S:494 E:508 ||| JJ
reproducibility ||| S:508 E:523 ||| NN
,  ||| S:523 E:525 ||| ,
the  ||| S:525 E:529 ||| DT
limitations  ||| S:529 E:541 ||| NNS
of  ||| S:541 E:544 ||| IN
retinal  ||| S:544 E:552 ||| JJ
imaging  ||| S:552 E:560 ||| NN
and  ||| S:560 E:564 ||| CC
the  ||| S:564 E:568 ||| DT
problems  ||| S:568 E:577 ||| NNS
of  ||| S:577 E:580 ||| IN
segmenting  ||| S:580 E:591 ||| VBG
of  ||| S:591 E:594 ||| IN
the  ||| S:594 E:598 ||| DT
retinal  ||| S:598 E:606 ||| JJ
layers  ||| S:606 E:613 ||| NNS
have  ||| S:613 E:618 ||| VBP
to  ||| S:618 E:621 ||| TO
be  ||| S:621 E:624 ||| VB
taken  ||| S:624 E:630 ||| VBN
into  ||| S:630 E:635 ||| IN
account ||| S:635 E:642 ||| NN
.  ||| S:642 E:644 ||| .
While  ||| S:644 E:650 ||| IN
the  ||| S:650 E:654 ||| DT
first  ||| S:654 E:660 ||| JJ
studies  ||| S:660 E:668 ||| NNS
were  ||| S:668 E:673 ||| VBD
limited  ||| S:673 E:681 ||| VBN
to  ||| S:681 E:684 ||| TO
single  ||| S:684 E:691 ||| JJ
sessions  ||| S:691 E:700 ||| NNS
in  ||| S:700 E:703 ||| IN
small  ||| S:703 E:709 ||| JJ
groups ||| S:709 E:715 ||| NNS
,  ||| S:715 E:717 ||| ,
further  ||| S:717 E:725 ||| JJ
trials  ||| S:725 E:732 ||| NNS
will  ||| S:732 E:737 ||| MD
elucidate  ||| S:737 E:747 ||| VB
how  ||| S:747 E:751 ||| WRB
the  ||| S:751 E:755 ||| DT
retinal  ||| S:755 E:763 ||| FW
nerve  ||| S:763 E:769 ||| FW
fibre  ||| S:769 E:775 ||| FW
layer  ||| S:775 E:781 ||| FW
( ||| S:781 E:782 ||| -LRB-
RNFL ||| S:782 E:786 ||| NNP
)  ||| S:786 E:788 ||| -RRB-
is  ||| S:788 E:791 ||| VBZ
altered  ||| S:791 E:799 ||| VBN
in  ||| S:799 E:802 ||| IN
the  ||| S:802 E:806 ||| DT
course  ||| S:806 E:813 ||| NN
of  ||| S:813 E:816 ||| IN
different  ||| S:816 E:826 ||| JJ
episodic  ||| S:826 E:835 ||| JJ
forms  ||| S:835 E:841 ||| NNS
of  ||| S:841 E:844 ||| IN
multiple  ||| S:844 E:853 ||| JJ
sclerosis ||| S:853 E:862 ||| NN
.  ||| S:862 E:864 ||| .
This  ||| S:864 E:869 ||| DT
review  ||| S:869 E:876 ||| NN
points  ||| S:876 E:883 ||| VBZ
out  ||| S:883 E:887 ||| RP
that  ||| S:887 E:892 ||| IN
the  ||| S:892 E:896 ||| DT
examination  ||| S:896 E:908 ||| NN
technique  ||| S:908 E:918 ||| NN
already  ||| S:918 E:926 ||| RB
provides  ||| S:926 E:935 ||| VBZ
comprehensive  ||| S:935 E:949 ||| JJ
information ||| S:949 E:960 ||| NN
,  ||| S:960 E:962 ||| ,
valuable  ||| S:962 E:971 ||| JJ
in  ||| S:971 E:974 ||| IN
the  ||| S:974 E:978 ||| DT
daily  ||| S:978 E:984 ||| JJ
care  ||| S:984 E:989 ||| NN
of  ||| S:989 E:992 ||| IN
neurological  ||| S:992 E:1005 ||| JJ
patients ||| S:1005 E:1013 ||| NNS
.  ||| S:1013 E:1015 ||| .
